Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenomics of third-generation aromatase inhibitors.

Expert opinion on pharmacotherapy - 1 Jun 2012

Turkistani Abdullah, Marsh Sharon

Abstract excerpt

INTRODUCTION: Breast cancer is a common, life-threatening disease among women. Contemporary hormonal therapy with third-generation aromatase inhibitors for estrogen-receptor-positive breast cancers in postmenopausal women is still facing the challenge of interpatient variability in therapeutic response and intensity of adverse effects. AREAS COVERED: This review highlights up-to-date literature regarding genomic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aromatase
Share to Aromatase Inhibitors
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Patient Selection

Share to Pharmacogenetics

Share to Polymorphism, Genetic

Share to Risk Assessment

Share to Treatment Outcome

Source

Identifiers

PMID: 22594760
DOI: 10.1517/14656566.2012.687721

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenomics of third-generation aromatase inhibitors.PMID 22594760Read ↗

The implications of genetic variation for the pharmacokinetics and pharmacodynamics of aromatase inhibitors.Semantic proximity Read ↗

The influence of genetic polymorphisms on the efficacy and side effects of anastrozole in postmenopausal breast cancer patients.Semantic proximity Read ↗

Pharmacogenetics of Aromatase Inhibitors in Endocrine Responsive Breast Cancer: Lessons Learnt from Tamoxifen and CYP2D6 Genotyping.Semantic proximity Read ↗

Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors.Semantic proximity Read ↗

Association of CYP19A1 gene variations with adjuvant letrozole-induced adverse events in South Indian postmenopausal breast cancer cohort expressing hormone-receptor positivity.Semantic proximity Read ↗

Pharmacogenetics and aromatase inhibitor induced side effects in breast cancer patients.Semantic proximity Read ↗

Pharmacogenomics of endocrine therapy in breast cancer.Semantic proximity Read ↗

No Evidence of Genotype‒Treatment Interactions between Endocrine Therapies and Adverse Drug Effects in Women with Breast Cancer: Findings from the UK BiobankSemantic proximity Read ↗

Genetic prediction of long-term effects of aromatase inhibition on cancer and non-neoplastic disease riskSemantic proximity Read ↗

Significance of the Estrogen Hormone and Single Nucleotide Polymorphisms in the Progression of Breast Cancer among Female.Semantic proximity Read ↗

Pharmacogenetics of endocrine therapy for breast cancer.Semantic proximity Read ↗

CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.